Axsome Therapeutics (AXSM) Assets Average (2016 - 2026)

Axsome Therapeutics has disclosed Assets Average across 11 years of filings, most recently posting $701.7 million for Q1 2026.

• Assets Average for Q1 2026 came in at $701.7 million, up 20.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $701.7 million (up 20.45% YoY), and the FY2025 annual result was $629.2 million, up 8.78% from the prior year.
• Assets Average came in at $701.7 million for Q1 2026 at Axsome Therapeutics, up from $679.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $701.7 million in Q1 2026 to a low of $88.2 million in Q1 2022.
• The 5-year median for Assets Average is $565.0 million (2024), against an average of $491.2 million.
• Across the five-year window, Assets Average slumped 50.05% in 2022 and jumped 308.66% in 2023, its largest moves.
• Axsome Therapeutics' Assets Average stood at $335.2 million in 2022, then surged by 77.36% to $594.5 million in 2023, then declined by 4.97% to $565.0 million in 2024, then advanced by 20.28% to $679.5 million in 2025, then rose by 3.26% to $701.7 million in 2026.
• The last three Assets Average figures came in at $701.7 million (Q1 2026), $679.5 million (Q4 2025), and $654.5 million (Q3 2025), per Business Quant data.